In contrast, NECs have intermediate tumor mutational burden with an average of 5.45/Mb and frequent alterations in TP53, KRAS, RB1, CSMD3, APC, CSMD1, LRATD2, TRRAP, and MYC [32,34]. The gene discussed is KRAS; the disease is neoplasm.